- Home
- NAZ vs VERU Comparison
NAZ vs VERU Comparison
Compare NAZ & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAZ
- VERU
- Stock Information
- Founded
- NAZ 1992
- VERU 1971
- Country
- NAZ United States
- VERU United States
- Employees
- NAZ N/A
- VERU N/A
- Industry
- NAZ Finance/Investors Services
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- NAZ Finance
- VERU Health Care
- Exchange
- NAZ Nasdaq
- VERU Nasdaq
- Market Cap
- NAZ 136.2M
- VERU 113.1M
- IPO Year
- NAZ N/A
- VERU 1990
- Fundamental
- Price
- NAZ $11.83
- VERU $0.86
- Analyst Decision
- NAZ
- VERU Strong Buy
- Analyst Count
- NAZ 0
- VERU 4
- Target Price
- NAZ N/A
- VERU $4.00
- AVG Volume (30 Days)
- NAZ 18.3K
- VERU 578.7K
- Earning Date
- NAZ 01-01-0001
- VERU 12-06-2024
- Dividend Yield
- NAZ 3.69%
- VERU N/A
- EPS Growth
- NAZ N/A
- VERU N/A
- EPS
- NAZ N/A
- VERU N/A
- Revenue
- NAZ N/A
- VERU $14,091,909.00
- Revenue This Year
- NAZ N/A
- VERU N/A
- Revenue Next Year
- NAZ N/A
- VERU N/A
- P/E Ratio
- NAZ N/A
- VERU N/A
- Revenue Growth
- NAZ N/A
- VERU N/A
- 52 Week Low
- NAZ $9.22
- VERU $0.36
- 52 Week High
- NAZ $11.37
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- NAZ 55.18
- VERU 53.67
- Support Level
- NAZ $11.69
- VERU $0.80
- Resistance Level
- NAZ $11.88
- VERU $1.00
- Average True Range (ATR)
- NAZ 0.07
- VERU 0.06
- MACD
- NAZ -0.00
- VERU 0.01
- Stochastic Oscillator
- NAZ 58.38
- VERU 49.81
About NAZ Nuveen Arizona Quality Municipal Income Fund
Nuveen Arizona Quality Municipal Income Fund is a closed-end management investment company. Its primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes. The fund's secondary objective is to enhance the portfolio value relative to the Arizona municipal bond market through investments in tax-exempt Arizona Municipal Obligations that, in the opinion of the Fund's investment adviser, are underrated or undervalued or represent municipal market sectors that are undervalued.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.